TuHURA Biosciences
TAMPA, FL · Biotechnology, Health Care, Therapeutics · 23 employees
Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s technologies are designed to overcome primary and acquired resistance to checkpoint inhibitors or cellular therapies in the treatment of cancer.
Funding history
- Debt Financing — $50.0M — Apr 2026
- Private Equity — $12.5M — Jun 2025
- Seed — $1.7M — Dec 2023
- Venture - Series Unknown — $5.1M — Nov 2021
- Seed — $2.7M — Dec 2020
Recent signals
- Apr 22, 2026: Raised $50.0M in Debt Financing
- Mar 23, 2026: TuHURA Biosciences Appoints Dr. Craig L. Tendler as Chief Medical Officer
- Jun 03, 2025: Raised $12.5M in Private Equity
- Apr 07, 2025: TuHURA Appoints Bertrand Le Bourdonnec as Executive Vice President
- Jul 08, 2024: TuHURA Biosciences Enters Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
- Dec 27, 2023: Raised $1.7M in Seed
- Nov 19, 2021: Raised $5.1M in Venture - Series Unknown
- Dec 17, 2020: Raised $2.7M in Seed
See plans & pricing → Track TuHURA Biosciences’s funding, hiring, and signals — with verified contacts — on Fundz.